about
Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer.Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysisRisk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid ArthritisThe missing cause approach to unmeasured confounding in pharmacoepidemiology.The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery.Comparison of alternative models for linking drug exposure with adverse effects.Evidence of subgroup-specific treatment effect in the absence of an overall effect: is there really a contradiction?Reducing the variance of the prescribing preference-based instrumental variable estimates of the treatment effect.Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery?Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure.Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failureNonlinear and time-dependent effects of sparsely measured continuous time-varying covariates in time-to-event analysisAssociations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid ArthritisAsthma is not associated with the need for surgery in Crohn's disease when controlling for smoking status: a population-based cohort studyDetermination of the time-dependent association between ciprofloxacin consumption and ciprofloxacin resistance using a weighted cumulative exposure model compared with standard models
P50
Q33783059-30E311FF-DBC1-4509-A6F4-C406CF4AAF99Q35910779-A479014A-68AA-4DCD-A60B-B3EE1EC4F200Q36033348-4D808439-14BB-4133-A19D-B9AF28F90C36Q37169479-9CEBE33B-AEB8-48F7-AD56-E504B8D36D45Q39955854-56E1ACBB-A314-46B5-BA04-778AAE5C14ECQ40908924-C0F434F4-A0C5-421E-8C87-2A445D409037Q43843712-36EE150C-BD93-4E11-B747-9BEFD986A0F1Q45196767-905C0C1D-71FB-4BAA-947B-A495B962BB20Q45881957-9588B611-EC95-42B3-95BB-378AFB59C570Q46863441-5B94F787-701C-49D4-AB68-2029D90734E1Q48242991-94C8833A-80E5-4587-B6B4-95D094D6CBA9Q89208535-B4C76F50-AAEA-4712-A790-12EC2CB90121Q89542347-04042A58-274D-4328-A5D0-969B7F3A61E3Q90030586-33F5E0C5-978B-4635-BB71-CD0DE3911F4FQ90429453-38F39E4B-9026-4975-AC3B-91048AF073F8Q94679600-2EFDDAD1-4F2B-40F7-ACD7-65B1DFFD4BD5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marie-Eve Beauchamp
@ast
Marie-Eve Beauchamp
@en
Marie-Eve Beauchamp
@es
Marie-Eve Beauchamp
@nl
type
label
Marie-Eve Beauchamp
@ast
Marie-Eve Beauchamp
@en
Marie-Eve Beauchamp
@es
Marie-Eve Beauchamp
@nl
prefLabel
Marie-Eve Beauchamp
@ast
Marie-Eve Beauchamp
@en
Marie-Eve Beauchamp
@es
Marie-Eve Beauchamp
@nl
P106
P1153
53263080100
P31
P496
0000-0001-9488-0157